Clinical trials: Schizophrenia and Disorders With Psychotic Features
Schizophrenia, Psychosis
Enhancing Rehabilitation for Veterans With Serious Mental Illness
This study addresses the critical need for innovative therapeutic interventions in Veterans with serious mental illnesses (SMI) receiving care in VA Psychosocial Rehabilitation and Recovery Centers (PRRCs).
- Conditions
- Schizophrenia, Psychosis, Serious Mental Illness, PTSD
- Trial name
- NCT06586164
- Testing
- Targeted Cognitive Training
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- VA Office of Research and Development
Schizophrenia
Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia
The purpose of the study is to investigate whether blockade of the histamine H2 receptors in the brain will have any beneficial effect on the symptoms of subjects with schizophrenia.
- Trial name
- NCT00565175
- Testing
- famotidine
- Where
- 5 sites in Finland
- Volunteers
- 30 people
- Sponsor
- Jesper Ekelund
Schizophrenia
Treating Psychotic Symptoms of Young Individuals Presenting a First Episode of Schizophrenia: Comparison of Two State-of-the-Art Interventions
To verify the efficacy of a group cognitive-behavioral therapy approach to lessening psychotic symptoms of individuals with a first episode of psychosis, and to compare its effects to a known skills training approach and a…
- Trial name
- NCT00358709
- Testing
- Cognitive-Behavioral therapy and Symptom Management
- Where
- Canada
- Volunteers
- 129 people
- Sponsor
- University of British Columbia
Schizophrenia, Schizophrenia Spectrum Disorder
tDCS and Executive Function Training for Schizophrenia
Schizophrenia-spectrum disorders are the most persistent, debilitating, and economically burdensome mental illnesses worldwide. Cognitive remediation (CR) is a psychological intervention based on principles of learning and…
- Conditions
- Schizophrenia, Schizophrenia Spectrum Disorder, Schizophrenia and Related Disorders
- Trial name
- NCT05389345
- Testing
- Transcranial direct current stimulation, Executive function training
- Where
- Canada
- Sponsor
- University of Toronto
Gambling Disorder, Psychotic Disorders
Prospective Multicenter Cohort Study Evaluating the Incidence and Risk Factors for Problem Gambling Among Young Adults With First-episode Psychosis
The aims of this propsective cohort study are to get a better understanding of the association between problem gambling and psychotic disorders among young adults with first-episode psychosis.
- Trial name
- ANTE-UP (NCT05686772)
- Testing
- Antipsychotic use, Psychiatric comorbidities, Sociodemographics/socioeconomic status
- Where
- 2 sites in Canada
- Volunteers
- 520 people
- Sponsor
- Laval University
Bipolar Disorder, Depression
Pediatric Bipolar Registry
The goal of the Pediatric Bipolar Registry (PBR) is to provide a comprehensive assessment regarding the diagnosis and treatment of pediatric bipolar disorder to children and adolescents with any current mood state and/or…
- Conditions
- Bipolar Disorder, Depression, Mania, Psychosis
- Trial name
- PBR (NCT02360267)
- Where
- United States
- Volunteers
- 334 people
- Sponsor
- The University of Texas Health Science Center, Houston
Schizophrenia; Psychosis
Pharmacologic Modulation of Hippocampal Activity in Psychosis
The purpose of this study is to test whether administration of levetiracetam (LEV), a commonly used anti-epileptic that alters neurotransmitter release, can reduce hippocampal hyperactivity.
- Trial name
- NCT04277936
- Testing
- Levetiracetam 500 mg
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
The goal of this clinical trial is to evaluate if the investigational drug, RL-007, can improve the cognitive performance of subjects with schizophrenia. The main questions the study aims to answer are: 1.
- Conditions
- Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia
- Trial name
- NCT05686239
- Testing
- RL-007 (Inidascamine)
- Where
- 36 sites in United States, Bulgaria and 2 more
- Volunteers
- 242 people
- Sponsor
- Recognify Life Sciences
Schizophrenia, Bipolar Affective Disorder
Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for Treatment of Schizophrenia or Bipolar Affective Disorder
The goal of this observational study is to evaluate the quality of life, drug safety and therapy compliance of schizophrenia or bipolar affective disorder patients during the treatment with quetiapine monotherapy or in…
- Trial name
- NCT07858565
- Testing
- Quetiapine (drug), quetiapine + aripiprazole, quetiapine + haloperidol
- Where
- Bosnia and Herzegovina
- Volunteers
- 500 people
- Sponsor
- Bosnalijek D.D
Paranoia
TReating Unhelpful Suspicious Thoughts in Adolescents (TRUST): a School-based Case Series
The goal of this acceptability and feasibility trial is to identify whether a six-session intervention for suspicious thoughts is feasible and acceptable to school-based adolescents.
- Trial name
- TRUST (NCT06975228)
- Testing
- TRUST
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- University of Sheffield
Schizophrenic Disorder, Cognitive Impairment
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
The purpose of this grant is to evaluate the efficacy of sodium butyrate as a novel treatment for cognitive deficits in schizophrenia (SZ).
- Trial name
- NCT03010865
- Testing
- Sodium Butyrate
- Where
- China
- Sponsor
- Shanghai Mental Health Center
Ketamine Abuse, Psychotic Disorders
Substance Misuse To Psychosis for Ketamine (SToP-K)
Evidence suggests that repeated or chronic ketamine use, as compared to acute ketamine users, posed a higher clinical risk of developing psychotic disorders, potentially related to the underlying chronic N-methyl-D-aspartate…
- Conditions
- Ketamine Abuse, Psychotic Disorders, Substance Use Disorders, Schizophrenia
- Trial name
- NCT03485339
- Testing
- genome testing
- Where
- 2 sites in Hong Kong
- Volunteers
- 162 people
- Sponsor
- The University of Hong Kong
Schizophrenia, Mental Disorder
Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia
To determine the safety and tolerability of multiple-dose administrations of aripiprazole intramuscular (IM) depot in the deltoid muscle in adult subjects with schizophrenia
- Conditions
- Schizophrenia, Mental Disorder, Nervous System Diseases
- Trial name
- NCT01909466
- Testing
- Aripiprazole, OPC-14597
- Where
- 11 sites in United States
- Volunteers
- 141 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Dance/Movement Therapy for Bone Mineral Density in Schizophrenia
Fractures are common accidents for long-term hospitalized patients with schizophrenia (SZ) in psychiatric hospitals, and once they occur, patients usually endure the pain of fractures for a long time.
- Trial name
- NCT05716802
- Testing
- dance/movement therapy, treatment as usual
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hebei Province Veterans Hospital
Schizophrenia
Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia
This is a multiple oral dose, randomized, double-blind, placebo-controlled study assessing the safety, tolerability and pharmacokinetics (PK) of SEP-363856 when administered qhs to Japanese subjects with schizophrenia.
- Trial name
- NCT04325737
- Testing
- SEP-363856
- Where
- 8 sites in Japan
- Volunteers
- 13 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Refractory Auditory Hallucinations, Schizophrenia
RTMS for Refractory Auditory Hallucinations Based on Personalized Targets Using Magnetoencephalography
This study is an before-after study in the same patient, which enrolled 36 psychiatric patients with refractory auditory hallucinations.
- Trial name
- NCT06802939
- Testing
- rTMS
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)
The purpose of this study is to assess whether SCH 900435 (Org 25935) 16 mg twice daily is more effective than placebo in the treatment of patients with schizophrenia, using olanzapine 15 mg once daily as active control.
- Trial name
- GUEST (NCT00988728)
- Testing
- SCH 900435 (Org 25935), Olanzapine
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia, Bipolar Disorder
App and Body Fat Scale in the Management of Overweight Patients
This study tests whether using a health app (Huawei Health) and a smart body fat scale can help overweight patients with schizophrenia or bipolar disorder lose weight and stay engaged in their health. What We're Testing: 1.
- Conditions
- Schizophrenia, Bipolar Disorder, Metabolic Syndrome, Overweight and Obesity
- Trial name
- NCT05866107
- Testing
- Effectiveness and Feasibility of Self-Monitoring for Weight Management in Individuals with Mental Disorders Using Digital Intervention ("SWIM" trial)
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Capital Medical University
Schizophrenia, Schizoaffective Disorder
Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia
Schizophrenia is marked by problems in attention, memory and problem solving. These deficits predict long-term functional outcome such as the ability to live independently and maintain employment, but they are not ameliorated by…
- Trial name
- NCT02069392
- Testing
- Cognitive remediation training, Nicotine polacrilex lozenge
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Psychotic Disorders
Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone
To assess the effect of risperidone 2 mg daily (QD) on the differential sensitivity of 2 spatial working memory tests (the GMLT and MDR) in non-agitated, drug-naive patients suffering from first-episode…
- Trial name
- NCT00174200
- Testing
- Risperidone 2 mg
- Where
- 3 sites in Canada, Russia
- Volunteers
- 20 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.